NetworkNewsBreaks – Predictive Oncology Inc. (NA
Post# of 281
(Total Views: 149)
Posted On: 09/27/2019 5:31:41 PM
NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Bringing Precision Medicine Tools to Physicians
Predictive Oncology (NASDAQ: POAI) is assisting clinicians and researchers in improving outcomes for cancer patients via its AI-driven, tumor-profiling platform. A recent article discussing the company reads, “POAI’s technology combines its database of evidence documenting actual drug responses of cancer patients’ tumors with artificial intelligence (AI) to create an invaluable predictive tool for clinicians and researchers. Predictive Oncology’s data offers a valuable, customizable assessment method that can be used by oncologists to determine the best drug for fighting a specific patient’s cancer. This disruptive technology is the first of its kind and is also meeting a critical need in the pharmaceutical, diagnostic and biotech industries to speed up the search for new precision therapies by providing tools to better predict how new drugs work on different cancers (http://nnw.fm/B4htL). . . . POAI’s wholly owned subsidiaries — Helomics and TumorGenesis — are working together to bring these important precision-medicine tools to physicians.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI) is assisting clinicians and researchers in improving outcomes for cancer patients via its AI-driven, tumor-profiling platform. A recent article discussing the company reads, “POAI’s technology combines its database of evidence documenting actual drug responses of cancer patients’ tumors with artificial intelligence (AI) to create an invaluable predictive tool for clinicians and researchers. Predictive Oncology’s data offers a valuable, customizable assessment method that can be used by oncologists to determine the best drug for fighting a specific patient’s cancer. This disruptive technology is the first of its kind and is also meeting a critical need in the pharmaceutical, diagnostic and biotech industries to speed up the search for new precision therapies by providing tools to better predict how new drugs work on different cancers (http://nnw.fm/B4htL). . . . POAI’s wholly owned subsidiaries — Helomics and TumorGenesis — are working together to bring these important precision-medicine tools to physicians.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Predictive Oncology Inc. (POAI) Stock Research Links
Scroll down for more posts ▼